{
  "id": "e7441413-be12-4b6b-be7e-9dc5fadc610d",
  "title": "Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug",
  "link": "https://economictimes.indiatimes.com/markets/stocks/news/biocon-shares-in-focus-after-unit-receives-usfda-nod-for-cancer-drug/articleshow/120189190.cms",
  "description": "Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.",
  "author": "",
  "published": "Fri, 11 Apr 2025 09:16:24 +0530",
  "source": "https://economictimes.indiatimes.com/rssfeedsdefault.cms",
  "categories": null,
  "byline": "ETMarkets.com",
  "length": 2876,
  "excerpt": "Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.",
  "siteName": "Economic Times",
  "favicon": "",
  "text": "Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drugBiocon shares rally nearly 6% after unit receives USFDA nod for cancer drugETMarkets.comLast Updated: Apr 11, 2025, 09:33:00 AM ISTBiocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.AgenciesBiocon gets USFDA nod for cancer biosimilar Jobevne, its 7th U.S. approval.Shares of Biocon rallied 5.6% to an intraday high of Rs 322.25 on the BSE on Friday after its subsidiary, Biocon Biologics, announced it had received approval from the U.S. Food and Drug Administration (USFDA) to market Jobevne (bevacizumab-nwgd), a biosimilar to Avastin, for the intravenous treatment of various cancers.Jobevne is a recombinant humanized monoclonal antibody that functions as a VEGF inhibitor, helping to combat tumors by blocking blood vessel growth.This marks Biocon’s seventh biosimilar approved in the U.S., further strengthening its oncology portfolio. The company already markets the drug in Europe and Canada under the brand name Abeymy.CEO and MD Shreehas Tambe described the approval as a significant milestone that reinforces Biocon’s commitment to expanding access to treatment.Bevacizumab sales in the U.S. reached approximately $2 billion in 2023.Live EventsShares of the pharma company have risen 10% in the past year but underperformed its sector by 1.59%. Over the last three years, the stock has declined by 14%.Read More News on(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price...moreless(You can now subscribe to our ETMarkets WhatsApp channel)Read More News on(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price...morelessStories you might be interested in",
  "image": "https://img.etimg.com/thumb/msid-120189174,width-1200,height-630,imgsize-347024,overlay-etmarkets/articleshow.jpg",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e  \u003cmain tabindex=\"-1\" role=\"presentation\" aria-hidden=\"true\"\u003e\u003cheader\u003e\u003c/header\u003e\u003cdiv data-key=\"\" data-et=\"2025-04-11 20:45:35.568\" data-ga-category=\"WEB Articleshow Clicks\" data-blacklist=\"0\" data-article_id=\"120189190\" data-hostid=\"153\" data-artitype=\"ET Free\" data-artdate=\"Apr 11, 2025, 09:16:00 AM IST\" data-arttitle=\"Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug\" data-artseo=\"markets/stocks/news/biocon-shares-in-focus-after-unit-receives-usfda-nod-for-cancer-drug\" data-agency=\"ETMarkets.com\" data-authors=\"\" data-artidate=\"Apr 11, 2025, 09:16:00 AM IST\" data-hyp1=\"biocon,biocon usfda approval,jobevne biosimilar,avastin alternative,biocon biologics news,vegf inhibitor cancer drug,bevacizumab-nwgd,oncology biosimilars,biocon cancer treatment,abeymy europe canada\" data-keywords=\"biocon,biocon usfda approval,jobevne biosimilar,avastin alternative,biocon biologics news,vegf inhibitor cancer drug,bevacizumab-nwgd,oncology biosimilars,biocon cancer treatment,abeymy europe canada\" data-publish-type=\"Native - 120189190\" data-audcnt=\"No\" data-vidcnt=\"No\" data-age=\"\u0026lt;72hrs\" data-no-of-words=\"162.0\" data-subsec2=\"2146842\"\u003e\u003cdiv\u003e\u003ch3 data-ga-action=\"Filter\"\u003e\u003cspan\u003e\u003c/span\u003e\u003c/h3\u003e\u003ch2\u003eBiocon shares rally nearly 6% after unit receives USFDA nod for cancer drug\u003c/h2\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv\u003eBiocon shares rally nearly 6% after unit receives USFDA nod for cancer drug\u003c/div\u003e\u003cspan\u003eETMarkets.com\u003c/span\u003e\u003cspan\u003e\u003c/span\u003e\u003ctime data-dt=\"1744344180000\"\u003eLast Updated: Apr 11, 2025, 09:33:00 AM IST\u003c/time\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv\u003e\u003ch2\u003eBiocon\u0026#39;s shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon\u0026#39;s seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.\u003c/h2\u003e\u003c/div\u003e\u003carticle competitionclients=\"\" currency_ad=\"1\" data-apw=\"1\" data-company-id=\"2082\"\u003e\u003cdiv\u003e\u003cfigure\u003e\u003cimg height=\"158\" width=\"210\" alt=\"Biocon shares in focus after unit receives USFDA nod for cancer drug\" src=\"https://img.etimg.com/thumb/msid-120189174,width-210,height-158,imgsize-347024,resizemode-75/biocon-shares-in-focus-after-unit-receives-usfda-nod-for-cancer-drug.jpg\"/\u003e\u003cspan\u003eAgencies\u003c/span\u003e\u003cfigcaption\u003eBiocon gets USFDA nod for cancer biosimilar Jobevne, its 7th U.S. approval.\u003c/figcaption\u003e\u003c/figure\u003e\u003c/div\u003e\u003cdiv data-brcount=\"11\"\u003eShares of \u003ca rel=\"dofollow\" href=\"https://economictimes.indiatimes.com/biocon-ltd/stocks/companyid-2082.cms\" data-ga-onclick=\"Inarticle articleshow link click#Markets#href\" target=\"_blank\"\u003eBiocon\u003c/a\u003e rallied 5.6% to an intraday high of Rs 322.25 on the BSE on Friday after its subsidiary, Biocon Biologics, announced it had received approval from the U.S. Food and Drug Administration (USFDA) to market Jobevne (\u003ca ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Markets#href\" href=\"https://economictimes.indiatimes.com/topic/bevacizumab-nwgd\" target=\"_blank\"\u003ebevacizumab-nwgd\u003c/a\u003e), a biosimilar to Avastin, for the intravenous treatment of various cancers.\u003cp\u003eJobevne is a recombinant humanized monoclonal antibody that functions as a VEGF inhibitor, helping to combat tumors by blocking blood vessel growth.\u003c/p\u003e\u003cbr/\u003eThis marks Biocon’s seventh biosimilar approved in the U.S., further strengthening its oncology portfolio. The company already markets the drug in Europe and Canada under the brand name Abeymy.\u003cp\u003eCEO and MD Shreehas Tambe described the approval as a significant milestone that reinforces Biocon’s commitment to expanding access to treatment.\u003c/p\u003e\u003cbr/\u003eBevacizumab sales in the U.S. reached approximately $2 billion in 2023.\u003cbr/\u003e\u003cdiv data-ga-impression=\"Events_widget_$pagename#Impression#url\"\u003e\u003cdiv\u003e\u003cimg alt=\"ET logo\" src=\"https://img.etimg.com/photo/118783427.cms\" width=\"90%\"/\u003e\u003c/div\u003e\u003ch3\u003eLive Events\u003c/h3\u003e\u003c/div\u003e\u003cbr/\u003eShares of the pharma company have risen 10% in the past year but underperformed its sector by 1.59%. Over the last three years, the stock has declined by 14%.\u003cbr/\u003e\u003c/div\u003e\u003cdiv data-ga-action=\"Widget Read More News\"\u003e\u003ch4\u003eRead More News on\u003c/h4\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv\u003e\u003cp\u003e(What\u0026#39;s moving \u003ca href=\"https://economictimes.indiatimes.com/indices/sensex_30_companies\"\u003eSensex\u003c/a\u003e and \u003ca href=\"https://economictimes.indiatimes.com/indices/nifty_50_companies\"\u003eNifty\u003c/a\u003e Track \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks\"\u003elatest market news\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks/recos\"\u003estock tips\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/budget\"\u003eBudget 2025\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks/live-blog/bse-sensex-today-live-updates-nifty-50-stock-market-on-union-budget-2025-nirmala-sitharaman-speech-01-february-2025/liveblog/117809746.cms\"\u003eShare Market on Budget 2025\u003c/a\u003e and \u003ca href=\"https://economictimes.indiatimes.com/markets/expert-view\"\u003eexpert advice\u003c/a\u003e, on \u003ca href=\"https://economictimes.indiatimes.com/markets\"\u003eETMarkets\u003c/a\u003e. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, \u003ca rel=\"nofollow\" href=\"https://t.me/joinchat/J60pKE7SOStsj5sI8nDmHQ\" target=\"_blank\"\u003esubscribe to our Telegram feeds\u003c/a\u003e .)\u003c/p\u003e \u003cp\u003eSubscribe to \u003ca rel=\"nofollow\" href=\"https://buy.indiatimes.com/ET/plans\"\u003eET Prime\u003c/a\u003e and read the \u003ca rel=\"nofollow\" href=\"https://epaper.indiatimes.com/timesepaper/publication-the-economic-times,city-delhi.cms\"\u003eEconomic Times ePaper\u003c/a\u003e Online.and \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks/live-blog/bse-sensex-today-live-nifty-stock-market-updates-5-june-2024/liveblog/110717623.cms\"\u003eSensex Today\u003c/a\u003e.\u003c/p\u003e \u003cp\u003eTop Trending Stocks: \u003ca href=\"https://economictimes.indiatimes.com/state-bank-of-india/stocks/companyid-11984.cms\"\u003eSBI Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/axis-bank-ltd/stocks/companyid-9175.cms\"\u003eAxis Bank Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/hdfc-bank-ltd/stocks/companyid-9195.cms\"\u003eHDFC Bank Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/infosys-ltd/stocks/companyid-10960.cms\"\u003eInfosys Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/wipro-ltd/stocks/companyid-12799.cms\"\u003eWipro Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/ntpc-ltd/stocks/companyid-12316.cms\"\u003eNTPC Share Price\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003cspan\u003e\u003cspan\u003e...\u003c/span\u003emore\u003c/span\u003e\u003cspan\u003eless\u003c/span\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv\u003e\u003cbr/\u003e\u003cem\u003e(You can now subscribe to our \u003ca rel=\"nofollow\" href=\"https://www.whatsapp.com/channel/0029VaAr2nxHbFV91x3BKx10\" target=\"_blank\" data-ga-onclick=\"WhtsApChnl#Click_Web#Markets\"\u003eETMarkets WhatsApp channel\u003c/a\u003e)\u003cbr/\u003e\u003c/em\u003e\u003c/div\u003e\u003cdiv data-ga-action=\"Widget Read More News\"\u003e\u003ch4\u003eRead More News on\u003c/h4\u003e\u003c/div\u003e\u003cdiv\u003e\u003cp\u003e(What\u0026#39;s moving \u003ca href=\"https://economictimes.indiatimes.com/indices/sensex_30_companies\"\u003eSensex\u003c/a\u003e and \u003ca href=\"https://economictimes.indiatimes.com/indices/nifty_50_companies\"\u003eNifty\u003c/a\u003e Track \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks\"\u003elatest market news\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks/recos\"\u003estock tips\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/budget\"\u003eBudget 2025\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks/live-blog/bse-sensex-today-live-updates-nifty-50-stock-market-on-union-budget-2025-nirmala-sitharaman-speech-01-february-2025/liveblog/117809746.cms\"\u003eShare Market on Budget 2025\u003c/a\u003e and \u003ca href=\"https://economictimes.indiatimes.com/markets/expert-view\"\u003eexpert advice\u003c/a\u003e, on \u003ca href=\"https://economictimes.indiatimes.com/markets\"\u003eETMarkets\u003c/a\u003e. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, \u003ca rel=\"nofollow\" href=\"https://t.me/joinchat/J60pKE7SOStsj5sI8nDmHQ\" target=\"_blank\"\u003esubscribe to our Telegram feeds\u003c/a\u003e .)\u003c/p\u003e \u003cp\u003eSubscribe to \u003ca rel=\"nofollow\" href=\"https://buy.indiatimes.com/ET/plans\"\u003eET Prime\u003c/a\u003e and read the \u003ca rel=\"nofollow\" href=\"https://epaper.indiatimes.com/timesepaper/publication-the-economic-times,city-delhi.cms\"\u003eEconomic Times ePaper\u003c/a\u003e Online.and \u003ca href=\"https://economictimes.indiatimes.com/markets/stocks/live-blog/bse-sensex-today-live-nifty-stock-market-updates-5-june-2024/liveblog/110717623.cms\"\u003eSensex Today\u003c/a\u003e.\u003c/p\u003e \u003cp\u003eTop Trending Stocks: \u003ca href=\"https://economictimes.indiatimes.com/state-bank-of-india/stocks/companyid-11984.cms\"\u003eSBI Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/axis-bank-ltd/stocks/companyid-9175.cms\"\u003eAxis Bank Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/hdfc-bank-ltd/stocks/companyid-9195.cms\"\u003eHDFC Bank Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/infosys-ltd/stocks/companyid-10960.cms\"\u003eInfosys Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/wipro-ltd/stocks/companyid-12799.cms\"\u003eWipro Share Price\u003c/a\u003e, \u003ca href=\"https://economictimes.indiatimes.com/ntpc-ltd/stocks/companyid-12316.cms\"\u003eNTPC Share Price\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003cspan\u003e\u003cspan\u003e...\u003c/span\u003emore\u003c/span\u003e\u003cspan\u003eless\u003c/span\u003e\u003c/div\u003e\u003c/article\u003e\u003c/div\u003e\u003c/div\u003e\u003c/main\u003e\u003cspan\u003e\u003c/span\u003e\u003cdiv\u003e\u003cspan\u003e\u003c/span\u003e\u003cp\u003eStories you might be interested in\u003c/p\u003e\u003cul\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "4 min read",
  "publishedTime": "2025-04-11T09:16:00+05:30",
  "modifiedTime": null
}
